Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

MetLife (MET)

NYSE: MET · Insurance—Life · New York, NY

Our rating: Neutral

Neutral reaffirmed at $101.67, moderate conviction, November 9, 2026.

Breaks if: The neutral call turns Cautious if ROE falls below 9% across two consecutive quarterly reports or the loss ratio rises above 102% in the next 10-Q — either would confirm that the underwriting and capital-return pressure is deepening rather than holding steady. It turns Positive if ROE rises above 14% across two straight quarterly reports while the loss ratio retreats below 95%, demonstrating that the 2.25× P/B premium has begun to earn its keep through expanding returns rather than multiple expansion alone.

Key figures

Market value$60.1B
Revenue, last 12 months$2.8B
Net income, last 12 months$5.1B
Free cash flow, last 12 monthsn/a
Price to earnings11.7×
Free cash flow yieldn/a
Dividend yield2.5%
Operating margin241.9%
Return on equity20.0%
Beta to the S&P 5000.94
Volatility, annualized25.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$728M17.2%$3.67n/a
June 30, 2026$724M19.9%$1.09n/a
March 31, 2026$734M20.1%$1.74n/a
December 31, 2025$600M7.9%$1.17n/a
September 30, 2025$621M12.1%$1.22n/a
June 30, 2025$604M8.2%$1.03n/a
March 31, 2025$611M5.9%$1.28n/a
December 31, 2024$556M−1.9%$1.77n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

18 ledger entries and 12 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.